New approaches to first-line treatment of advanced renal cell carcinoma.

Ther Adv Med Oncol · 2021 · PMC8435931 · PMID 34527080

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

A favorable trend was observed for the combination versus sunitinib for PFS irrespective of PD-L1 status, while for OS the benefit was more pronounced in patients with PD-L1–negative versus PD-L1–positive tumors.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.